Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

AARDA hopes to educate public on autoimmune diseases during March

March is National Autoimmune Diseases Awareness Month, and the American Autoimmune Related Diseases Association (AARDA) is working to educate the public on risk factors, prevalence, and the severe lack of awareness surrounding autoimmune diseases.

3 Mar 2012

Early surgical intervention stops seizures and improves quality of life

While the thought of any type of surgery can be disconcerting, the thought of brain surgery can be downright frightening. But for people with a particular form of epilepsy, surgical intervention can literally be life-restoring.

3 Mar 2012

Union County Commission honors KF scientist with Women of Excellence Award

Helen Genova, PhD, research scientist at Kessler Foundation, received a Women of Excellence Award in Health Sciences from the Union County Commission on the Status of Women. In the Foundation's Neuropsychology and Neuroscience Laboratory, she investigates the effects of multiple sclerosis (MS) and traumatic brain injury on cognitive function with grant funding.

3 Mar 2012

CLR01 blocks toxic aggregations of proteins in mouse model of Parkinson's

Millions of people suffer from Parkinson's disease, a disorder of the nervous system that affects movement and worsens over time. As the world's population ages, it's estimated that the number of people with the disease will rise sharply. Yet despite several effective therapies that treat Parkinson's symptoms, nothing slows its progression.

2 Mar 2012

Shipment of Fabrazyme commences from Genzyme's FDA-and-EMA-approved Framingham plant

Genzyme, a Sanofi company, today announced that it has begun shipping Fabrazyme (agalsidase beta) produced at its newly approved plant in Framingham, Massachusetts. As previously communicated, patients in the U.S. are now able to return to full dosing in March. In addition, all new patients in the U.S. are eligible to begin Fabrazyme treatment, at full dosing levels.

2 Mar 2012

Ekso Bionics, Kessler Foundation partner to test commercial robotic exoskeleton

On Monday, Kessler Foundation became the second rehabilitation research center in the U.S. to implement Ekso, a wearable, robotic battery-powered exoskeleton that allows wheelchair users with lower-extremity weakness to stand and walk.

2 Mar 2012

Parasitic worms could offer new treatment hope for MS patients

Parasitic worms could offer a new treatment hope for patients suffering from the autoimmune disease multiple sclerosis, scientists believe.

1 Mar 2012

SIR to showcase latest minimally invasive treatments at 37th annual meeting

Health, science and medical reporters are invited to register now for the Society of Interventional Radiology's 37th Annual Scientific Meeting March 24 at Moscone Center (North), San Francisco, Calif. The meeting's theme, "IR Evidence," was chosen to focus on the results of care-changing investigations that showcase research into minimally invasive treatments that provide treatment options, advance patient care and improve quality of life.

1 Mar 2012

KF's TBI research director to speak at Washington conference

Jordan Grafman, PhD, director of Traumatic Brain Injury Research at Kessler Foundation, is an invited speaker at The 2nd Annual Traumatic Brain Injury Conference on March 6, 2012, in Washington, DC. Dr. Grafman will describe the long-term cognitive and social consequences of traumatic brain injury.

1 Mar 2012

New research shows beneficial side effect of anti-allergy parasite

New research is showing a beneficial side effect of parasites for our health. Hygiene Hypothesis: As rates of allergy are reported to have tripled in the UK in the past decade, the scientific finger is pointing to an over-sanitised lifestyle making our immune responses overactive. Now, a team of biologists at the University of Edinburgh, led by Professor Rick Maizels, are investigating how parasitic worms could offer a cure for modern illnesses.

1 Mar 2012

Biogen Idec announces new easier to use injection for multiple sclerosis

The Food and Drug Administration approved the company's Avonex pen, an injection designed to reduce pain and anxiety when patients self-administer the drug. The FDA also approved a new dosing schedule for the drug intended to reduce flu-like symptoms often associated with the drug.

29 Feb 2012

Scientists to speak on cultural issues pertinent to rehabilitation research

Two scientists will represent Kessler Foundation at the 2012 Race, Ethnicity and Disabilities State of the Science Conference on March 1-2 at the Crystal Gateway Marriott in Arlington, Virginia.

29 Feb 2012

Minimally invasive treatments to be showcased at SIR's 37th Annual Scientific Meeting

The Society of Interventional Radiology will feature minimally invasive scientific advances and new discoveries that may change the way dozens of diseases are treated at its 37th Annual Scientific Meeting March 24-29 at San Francisco's Moscone Center.

29 Feb 2012

AAN, ALS Association announce creation of Richard Olney Clinician Scientist Development Award

The American Academy of Neurology Foundation and The ALS Association are announcing the creation of the Richard Olney Clinician Scientist Development Award in ALS, named after Richard K. Olney, MD, a leading neurologist and pioneer in clinical ALS research who died late last month of ALS, also known as amyotrophic lateral sclerosis, or Lou Gehrig's disease.

29 Feb 2012

Cannabinoids may be a target for new strategies in cancer treatment

Cannabis-like substances that are produced by the body have both therapeutic and harmful properties, besides their well-known intoxicating effects, and the body's cannabinoid system may be a target for new strategies in cancer treatment.

29 Feb 2012

Activating brain's visual cortex improves our sense of smell

A new study reveals for the first time that activating the brain's visual cortex with a small amount of electrical stimulation actually improves our sense of smell.

28 Feb 2012

Biogen Idec receives FDA approval for two separate dosing innovations to treat MS

Today Biogen Idec announced that the U.S. Food and Drug Administration (FDA) has approved two separate dosing innovations designed to improve the treatment experience for patients receiving once-a-week AVONEX for relapsing forms of multiple sclerosis (MS).

28 Feb 2012

Diets low in omega-3 fatty acids linked with memory problems

A diet lacking in omega-3 fatty acids, nutrients commonly found in fish, may cause your brain to age faster and lose some of its memory and thinking abilities, according to a study published in the February 28, 2012, print issue of Neurology, the medical journal of the American Academy of Neurology.

28 Feb 2012

Biogen Idec, Samsung Biologics establish joint venture to develop and market biosimilars

Samsung Biologics and Biogen Idec announced today that the companies have established their joint venture, Samsung Bioepis Co., Ltd., to develop, manufacture and market biosimilars in keeping with their agreement announced in December.

28 Feb 2012

Opexa 2011 net loss increases to $5,968,448

Opexa Therapeutics, Inc., a biotechnology company developing a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the year ended December 31, 2011 and provided an overview of corporate developments during the last year.

27 Feb 2012